Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary

Adverum Biotechnologies, Inc. announces participation in Ophthalmology Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference. Laurent Fischer, M.D., to speak on gene therapy for ocular diseases.

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44^th Annual Health Care Conference on Tuesday, March 5^th, 2024 at 9:10 a.m. ET.

The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the presentation.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Inquiries:
Adverum Investor Relations
Email: ir@adverum.com

FAQ

When is Laurent Fischer, M.D., participating in the Ophthalmology Corporate Panel Discussion?

Laurent Fischer, M.D., will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m. ET.

What is Adverum Biotechnologies' ticker symbol?

Adverum Biotechnologies' ticker symbol is ADVM.

Where can the on-demand webcast of the panel discussion be accessed?

The on-demand webcast of the panel discussion can be accessed under Events and Presentations in the Investors section of Adverum’s website.

How long will the replay of the webcast be available?

A replay of the webcast will be available on the website for at least 30 days following the presentation.